Core Viewpoint - The article discusses the accelerated clinical access and economic substitution of high-quality generic drugs in China due to the "volume-based procurement" policy, alongside the increasing proportion of biological drugs in national negotiations, which facilitates the listing and promotion of biosimilars in hospitals [3][4]. Group 1: Market Overview - The Chinese generic drug market has maintained a scale of approximately 900 billion yuan, with an increase in the number of companies and varieties intensifying market competition [3]. - As of 2024, the number of generic drugs that have passed consistency evaluation or are deemed equivalent has increased by over two-thirds compared to three years ago, primarily driven by a few companies and previously approved varieties [4][9]. - In the chemical generic drug sector, the top 10 companies hold a stable market share of around 22%, indicating a relatively low market concentration [7][9]. Group 2: Drug Evaluation and Approval - The number of approved generic drugs reached 914 in 2024, a significant increase from 543 in 2021, with 70% of these approvals concentrated among 33% of companies [9]. - The phenomenon of "homogenization of varieties" is becoming a defining characteristic of competition in the generic drug market, with a notable increase in the number of similar products [12][13]. Group 3: Biosimilars Market - By 2024, 87 biosimilars have been approved in China, with over 50% being antibody biosimilars, indicating a concentrated market in specific therapeutic areas [13]. - The application for biosimilars has reached a historical high, particularly in the metabolic field, with one drug alone accounting for nearly 40% of applications [13]. Group 4: Contract Manufacturing Trends - The participation of contract manufacturers in national drug procurement has significantly increased, with 31% of selected products in the tenth round of procurement being produced by contract manufacturers, up from 3% in the second round [16][19]. - The article highlights the challenges of ensuring quality control and regulatory compliance in contract manufacturing, especially as the number of B certificate enterprises increases [19][20].